In diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and pulmonary hypertension associated with interstitial lung disease (PH-ILD), diagnosis remains challenging, especially in the early stages. And improving when they are identified, as well as how knowledge is shared among specialists, is key to managing them.
In this context, Ferrer is promoting two initiatives that point in this direction: AXONIA, focused on rare neurodegenerative diseases, and the Expert Forums in HP-EPI, which are already connecting specialists in different parts of the world.
AXONIA (Advancing Expertise in Rare Neurodegenerative Diseases) was born with a clear objective: to improve the early diagnosis and early referral of diseases that are still difficult to identify in their early stages. In its first webinar, more than 330 healthcare professionals from Europe, America and Latin America connected to delve into tauopathies such as PSP, a disease whose early symptoms are often confused with other conditions or aging.
The session not only had a high participation: it registered maximum levels of satisfaction and an average attention time well above the standard, which reflects the real interest in this type of knowledge.
In parallel, Ferrer continues to expand the impact of its Expert Forums on lung diseases such as HP-EPI. After its deployment in Latin America and Europe, the initiative has reached the Middle East, bringing together opinion leaders from countries such as Saudi Arabia, the United Arab Emirates and Oman in a meeting focused on the exchange of real clinical experience.
In both cases, the objective is the same: to transform knowledge into clinical practice.
In complex diseases, access to the right information, at the right time, can make all the difference in clinical practice.
